Abstract
Trimetazidine, a metabolic agent with anti-ischemic properties, has strong evidence of efficacy and tolerability in the treatment of patients with ischemic cardiomyopathy, including subjects with chronic angina and heart failure. There is now a growing evidence that trimetazidine has also a positive impact on quality of life of these patients. This seems to be a consequence of the clinical benefits provided by trimetazidine on one hand, and of its optimal tolerability profile on the other. Benefits of trimetazidine administration include symptom relief, particularly reduction of episodes of angina and dyspnea with a resulting improvement in exercise tolerance. The clinical effectiveness of trimetazidine can alone explain its impact on quality of life in a disease, such as ischemic cardiomyopathy, where poor quality of life is strongly related to the limitation of daily living activities imposed by symptoms.
| Original language | English |
|---|---|
| Pages (from-to) | 28-31 |
| Number of pages | 4 |
| Journal | Heart and Metabolism |
| Issue number | 52 |
| Publication status | Published - 2011 |
Fingerprint
Keywords
- Ischemic cardiomyopathy
- Quality of life
- Trimetazidine
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine
- Endocrinology, Diabetes and Metabolism
Cite this
Quality of life with trimetazidine. / Marazzi, Giuseppe; Caminiti, Giuseppe; Volterrani, Maurizio.
In: Heart and Metabolism, No. 52, 2011, p. 28-31.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Quality of life with trimetazidine
AU - Marazzi, Giuseppe
AU - Caminiti, Giuseppe
AU - Volterrani, Maurizio
PY - 2011
Y1 - 2011
N2 - Trimetazidine, a metabolic agent with anti-ischemic properties, has strong evidence of efficacy and tolerability in the treatment of patients with ischemic cardiomyopathy, including subjects with chronic angina and heart failure. There is now a growing evidence that trimetazidine has also a positive impact on quality of life of these patients. This seems to be a consequence of the clinical benefits provided by trimetazidine on one hand, and of its optimal tolerability profile on the other. Benefits of trimetazidine administration include symptom relief, particularly reduction of episodes of angina and dyspnea with a resulting improvement in exercise tolerance. The clinical effectiveness of trimetazidine can alone explain its impact on quality of life in a disease, such as ischemic cardiomyopathy, where poor quality of life is strongly related to the limitation of daily living activities imposed by symptoms.
AB - Trimetazidine, a metabolic agent with anti-ischemic properties, has strong evidence of efficacy and tolerability in the treatment of patients with ischemic cardiomyopathy, including subjects with chronic angina and heart failure. There is now a growing evidence that trimetazidine has also a positive impact on quality of life of these patients. This seems to be a consequence of the clinical benefits provided by trimetazidine on one hand, and of its optimal tolerability profile on the other. Benefits of trimetazidine administration include symptom relief, particularly reduction of episodes of angina and dyspnea with a resulting improvement in exercise tolerance. The clinical effectiveness of trimetazidine can alone explain its impact on quality of life in a disease, such as ischemic cardiomyopathy, where poor quality of life is strongly related to the limitation of daily living activities imposed by symptoms.
KW - Ischemic cardiomyopathy
KW - Quality of life
KW - Trimetazidine
UR - http://www.scopus.com/inward/record.url?scp=84855662843&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84855662843&partnerID=8YFLogxK
M3 - Article
AN - SCOPUS:84855662843
SP - 28
EP - 31
JO - Heart and Metabolism
JF - Heart and Metabolism
SN - 1566-0338
IS - 52
ER -